19:53 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
23:20 , Jul 28, 2017 |  BC Extra  |  Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

BC8-I-131: Phase III started

Actinium began the open-label, Phase III SIERRA trial to compare Iomab-B vs. physician’s choice of chemotherapy as an induction and conditioning agent prior to allogeneic HSCT in about 150 patients ages >55 with relapsed or...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD45

Hematology INDICATION: Stem cell transplant Mouse studies suggest an anti- CD45 mAb-based antibody-drug conjugate (ADC) could help condition patients for hematopoietic stem cell transplants (HSCTs). In a mouse model of HSCT, an ADC consisting of...
07:00 , Jun 9, 2016 |  BC Innovations  |  Translation in Brief

Killing HSCs softly

In Nature Biotechnology this week, researchers from Harvard University mellowed the typically harsh preconditioning procedure for hematopoietic stem cell transplantation (HSCT). By using an antibody-drug conjugate (ADC) instead of irradiation, the team thinks it has...
07:00 , Jun 30, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
00:24 , Jun 25, 2014 |  BC Extra  |  Financial News

Actinium, Heron planning follow-ons

Late Tuesday, Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) and Heron Therapeutics Inc. (NASDAQ:HRTX) proposed follow-ons, but neither company disclosed how many shares they plan to issue or how much they expect to raise. Actinium's follow-on is underwritten...
01:49 , Dec 27, 2012 |  BC Extra  |  Financial News

Actinium raises $5.1M ahead of reverse-merger

Actinium Pharmaceuticals Inc. (Newark, N.J.) raised $5.1 million through the sale of about 9.3 million units in the first close of a bridge financing. Each unit comprises a share, a 120-day warrant to purchase a...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Iomab-B: Phase II data

A Phase II trial in 14 patients <50 years old with advanced AML or high-risk MDS showed that Iomab-B plus fludarabine and total body irradiation given before myeloablative HCT led to a PFS rate of...